These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37198513)

  • 21. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
    Leung C
    Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.
    Lahoz Fernandez PE; Miranda Pereira J; Fonseca Risso I; Baleeiro Rodrigues Silva P; Freitas Barboza IC; Vieira Silveira CG; Diogo Silva G; Marzorati Kuntz Puglia P; Genaro Mutarelli E
    Acta Neurol Scand; 2022 Apr; 145(4):393-398. PubMed ID: 34967005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors.
    Rzymski P
    Front Immunol; 2023; 14():1183258. PubMed ID: 37180147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination.
    Nishiguchi Y; Matsuyama H; Maeda K; Shindo A; Tomimoto H
    BMC Neurol; 2021 Nov; 21(1):452. PubMed ID: 34789193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guillain-​Barré Syndrome Associated with COVID-19 Vaccination.
    Shao SC; Wang CH; Chang KC; Hung MJ; Chen HY; Liao SC
    Emerg Infect Dis; 2021 Dec; 27(12):3175-3178. PubMed ID: 34648420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review.
    Lee HY; Lien WC
    Hum Vaccin Immunother; 2023 Dec; 19(1):2171231. PubMed ID: 36919452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports.
    Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA
    Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.
    Kaulen LD; Doubrovinskaia S; Mooshage C; Jordan B; Purrucker J; Haubner C; Seliger C; Lorenz HM; Nagel S; Wildemann B; Bendszus M; Wick W; Schönenberger S
    Eur J Neurol; 2022 Feb; 29(2):555-563. PubMed ID: 34668274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
    Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
    Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Patone M; Handunnetthi L; Saatci D; Pan J; Katikireddi SV; Razvi S; Hunt D; Mei XW; Dixon S; Zaccardi F; Khunti K; Watkinson P; Coupland CAC; Doidge J; Harrison DA; Ravanan R; Sheikh A; Robertson C; Hippisley-Cox J
    Nat Med; 2021 Dec; 27(12):2144-2153. PubMed ID: 34697502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study.
    Morciano C; Spila Alegiani S; Menniti Ippolito F; Belleudi V; Trifirò G; Zanoni G; Puccini A; Sapigni E; Mores N; Leoni O; Monaco G; Clagnan E; Zappetti C; Bovo E; Cutillo M; Da Cas R; Massari M
    PLoS One; 2024; 19(1):e0290879. PubMed ID: 38241309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Are the Risks of Guillain-Barré Syndrome After SARS-CoV-2 Infection and COVID-19 Vaccination?
    Bourdette D; Silbermann E
    Neurology; 2023 Nov; 101(20):875-876. PubMed ID: 37852787
    [No Abstract]   [Full Text] [Related]  

  • 33. Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.
    Lehmann HC; Oberle D; Keller-Stanislawski B; Rieck T; Streit R
    Euro Surveill; 2023 Jun; 28(24):. PubMed ID: 37318764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
    Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Case Report of Guillain-Barré Syndrome In Association with SARS-CoV-2 Vaccination in Malaysia.
    Sii HL; Ng SH; Wong VF; Law WC
    Acta Neurol Taiwan; 2023 Dec; 32(4)():207-211. PubMed ID: 37723913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Guillain-Barre syndrome and thrombocytopenia after SARS-CoV-2 vaccination with Moderna. A case report].
    Lázaro C; Llauradó A; Sánchez-Tejerina D; Cabirta A; Carpio C; Sotoca J; Salvadó M; Raguer N; Restrepo J; Juntas R
    Rev Neurol; 2022 Oct; 75(8):247-250. PubMed ID: 36218255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.
    Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L
    Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guillain-Barré syndrome after COVID-19 vaccination: report of two cases from Vietnam.
    Hai PD; Phuong LL; Tot NH; Anh NLP; Tung ND; Quan NH
    J Infect Dev Ctries; 2022 Nov; 16(11):1703-1705. PubMed ID: 36449641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: Case report and scope review.
    Liang H; Cao Y; Zhong W; Ma Z; Liu J; Chen H
    Hum Vaccin Immunother; 2022 Nov; 18(6):2125753. PubMed ID: 36315834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    Min YG; Ju W; Ha YE; Ban JJ; Lee SA; Sung JJ; Shin JY
    J Neuroimmunol; 2021 Oct; 359():577691. PubMed ID: 34416410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.